New Zealand - engelsk - Medsafe (Medicines Safety Authority)

multichem nz limited - cefazolin sodium 524mg equivalent to cephazolin 500 mg;   - powder for injection - 500 mg - active: cefazolin sodium 524mg equivalent to cephazolin 500 mg  

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - cefazolin sodium, quantity: 1.048 g - injection, powder for - excipient ingredients: - treatment of the following serious infections due to susceptible organisms: - respiratory tract infections due to strep. pneumoniae, klebsiella sp., h. influenzae, staph. aureus (penicillin sensitive and penicillin resistant) and group a beta-haemolytic streptococci. injectable benzathine penicillin is considered to be the drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefazolin is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available at present; - genitourinary tract infections due to e. coli, p. mirabilis, klebsiella sp. and some strains of enterobacter and enterococci; - skin and skin structure infections due to staph. aureus (penicillin sensitive and penicillin resistant), and group a beta-haemolytic streptococci and other strains of streptococci; - bone and joint infections due to staph. aureus; - septicaemia due to strep. pneumoniae, staph. aureus (penicillin sensitive and penicillin resistant), p. mirabilis, e. coli and klebsiella sp.; - endocarditis due to staph. aureus (penicillin sensitive and penicillin resistant) and group a beta-haemolytic streptococci.,appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - cefazolin sodium, quantity: 0.524 g - injection, powder for - excipient ingredients: - treatment of the following serious infections due to susceptible organisms: - respiratory tract infections due to strep. pneumoniae, klebsiella sp., h. influenzae, staph. aureus (penicillin sensitive and penicillin resistant) and group a beta-haemolytic streptococci. injectable benzathine penicillin is considered to be the drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefazolin is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available at present; - genitourinary tract infections due to e. coli, p. mirabilis, klebsiella sp. and some strains of enterobacter and enterococci; - skin and skin structure infections due to staph. aureus (penicillin sensitive and penicillin resistant), and group a beta-haemolytic streptococci and other strains of streptococci; - bone and joint infections due to staph. aureus; - septicaemia due to strep. pneumoniae, staph. aureus (penicillin sensitive and penicillin resistant), p. mirabilis, e. coli and klebsiella sp.; - endocarditis due to staph. aureus (penicillin sensitive and penicillin resistant) and group a beta-haemolytic streptococci.,appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

multichem nz limited - cefazolin sodium 524mg equivalent to cefazolin 500 mg;   - injection with diluent - 500 mg - active: cefazolin sodium 524mg equivalent to cefazolin 500 mg   excipient: water for injection

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - cefazolin sodium, quantity: 1048 mg (equivalent: cefazolin, qty 1000 mg) - injection, powder for - excipient ingredients: - cephazolin sodium injection is indicated in the treatment of the following serious infections due to susceptible organisms: 1. respiratory tract infections due to s. pneumoniae, klebsiella species, h. influenzae, staph. aureus (penicillin-sensitive and penicillin-resistant), and group a beta-haemolytic streptococci. injectable benzathine penicillin is considered to be the drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephazolin sodium is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cephazolin sodium in the subsequent prevention of rheumatic fever are not available at present 2. gentinourinary tract infections due to esch. coli, pr. mirabilis, klebsiella species and some strains of enterobacter and enterococci. 3. skin and soft-tissue infections due to staph. aureus (penicillin-sensitive and penicillin-resistant) and group a beta-haemolytic streptococci and other strains of streptococci. 4. bone and joint infections due to staph. aureus. 5. septicaemia due to s. pneumoniae, staph. aureus (penicillin-sensitive and penicillin- resistant), pr. mirabilia, esch. coli and klebsiella species. 6. endocarditis due to staph. aureus (penicillin-sensitive and penicillin-resistant) and group a beta-haemolytic streptococci. appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cephazolin sodium.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - cefazolin sodium, quantity: 524 mg (equivalent: cefazolin, qty 500 mg) - injection, powder for - excipient ingredients: - cephazolin sodium injection is indicated in the treatment of the following serious infections due to susceptible organisms: 1. respiratory tract infections due to s. pneumoniae, klebsiella species, h. influenzae, staph. aureus (penicillin-sensitive and penicillin-resistant), and group a beta-haemolytic streptococci. injectable benzathine penicillin is considered to be the drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephazolin sodium is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cephazolin sodium in the subsequent prevention of rheumatic fever are not available. 2. gentinourinary tract infections due to esch. coli, pr. mirabilis, klebsiella species and some strains of enterobacter and enterococci. 3. skin and soft-tissue infections due to staph. aureus (penicillin-sensitive and penicillin-resistant) and group a beta-haemolytic streptococci and other strains of streptococci. 4. bone and joint infections due to staph. aureus. 5. septicaemia due to s. pneumoniae, staph. aureus (penicillin-sensitive and penicillin- resistant), pr. mirabilia, esch. coli and klebsiella species. 6. endocarditis due to staph. aureus (penicillin-sensitive and penicillin-resistant) and group a beta-haemolytic streptococci. appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cephazolin sodium.

Kypros - gresk - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

codal-synto limited (0000010484) 21 constantinoupoleos str., limassol, 3011, 51785 (3508) - cefazolin sodium - powder for solution for injection/infusion - 500mg - cefazolin sodium (0027164461) 500mg - cefazolin

USA - engelsk - NLM (National Library of Medicine)

physicians total care, inc. - cefazolin sodium (unii: p380m0454z) (cefazolin - unii:ihs69l0y4t) - cefazolin sodium 500 mg in 10 ml - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefazolin for injection, usp and other antibacterial drugs, cefazolin for injection, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefazolin for injection, usp is indicated in the treatment of the following serious infections due to susceptible organisms: respiratory tract infections due to streptococcus pneumoniae, klebsiella species, haemophilus influenzae, staphylococcus aureus (penicillin-sensitive and penicillin-resistant) and group a beta-hemolytic streptococci. injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - cefazolin sodium 525mg equivalent to 500 mg cephazolin;   - powder for injection - 500 mg - active: cefazolin sodium 525mg equivalent to 500 mg cephazolin  

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - cefazolin sodium, quantity: 2096 mg - injection, powder for - excipient ingredients: - cefazolin is indicated in the treatment of the following serious infections due to susceptible organisms:,respiratory tract infections due to s. pneumoniae, klebsiella species, h. influenzae, staph. aureus (penicillin-sensitive and penicillin- resistant), and group a beta-haemolytic streptococci.,injectable benzathine penicillin is considered to be the drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever.,cefazolin is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available at present.,genitourinary tract infections due to esch. coli, pr. mirabilis, klebsiella species, and some strains of enterobacter and enterococci.,skin and skin structure infections due to staph. aureus (penicillin-sensitive and penicillin- resistant), and group a beta-haemolytic streptococci and other strains of streptococci.,bone and joint infections due to staph. aureus.,septicaemia due to s. pneumoniae, staph. aureus (penicillin-sensitive and penicillin-resistant), pr. mirabilis, esch. coli and klebsiella species.,endocarditis due to staph. aureus (penicillin-sensitive and penicillin-resistant), and group a beta-haemolytic streptococci.,appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin.